1. Introduction {#sec0005}
===============

Leiomyosarcoma (LMS) of the rectum was first described by Scott in 1923 [@bib0005]. In the former classification of smooth muscle tumor in the gastrointestinal tract, LMS was not distinguished from gastrointestinal stromal tumor (GIST). Since the discovery of the oncogenic role of KIT in 1998 [@bib0010], GISTs have been differentiated from other mesenchymal tumors such as leiomyomas, leiomyoblastomas, and LMSs [@bib0015]. Although 5% of tumors with the clinicopathologic features of GIST lack KIT expression, it is important to diagnose LMS definitively by immunohistochemical profiling of smooth muscle actin (SMA), desmin, and CD34 [@bib0020].

True LMS of the colorectum diagnosed by immunnohistochemical profiling is extremely rare, with a reported frequency of less than 0.1% of all malignancies of the colorectum [@bib0025]; only 13 reports with immunohistochemical definition which was performed properly have been published in reviews of resected gastrointestinal mesenchymal tumors after 1998 [@bib0030], [@bib0035], [@bib0040], [@bib0045], [@bib0050]. Furthermore, unlike adenocarcinomas, nodal involvement in LMS is unusual [@bib0055]. Herein we report an aggressive case of LMS in a rectosigmoid lesion with lymph node metastasis.

2. Case presentation {#sec0010}
====================

A 76-year-old woman visited our hospital complaining of intermittent anal bleeding that had lasted 5 months. An elevated tumor with central ulceration was found 10 cm from the anal verge by colonoscopy ([Fig. 1](#fig0005){ref-type="fig"}), and biopsy specimens revealed a spindle cell tumor. The MIB-1 labeling index was high (80%), suggesting a high-grade sarcoma. Abdominal CT scan revealed a 10 cm mass in the rectosigmoid that invaded the uterus ([Fig. 2](#fig0010){ref-type="fig"}). No distant metastases were observed. Laboratory tests revealed low-grade anemia (serum hemoglobin 12.8 g/dl), but no other abnormalities were noted; serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels were also normal ([Table 1](#tbl0005){ref-type="table"}).

Surgical resection with curative intent required rectal anterior resection with appendectomy, total hysterectomy, and bilateral salpingo-oophorectomy due to extensive inflammation involving the appendix, uterus, right ovary, and right fallopian tube. The excised mass was 110 × 80 × 60 mm in size. Routine hematoxylin and eosin staining showed proliferation of spindle-shaped tumor cells with enlarged nuclei and eosinophilic cytoplasm ([Fig. 3](#fig0015){ref-type="fig"}). Immunohistochemically, the tumor was positive for desmin and SMA, whereas c-kit, DOG1, CD34, and S-100 protein were not expressed ([Fig. 4](#fig0020){ref-type="fig"}). The tumor was of high cellularity, with up to 10 mitoses per high-power field (HPF) and variable areas of necrosis. Direct invasion was histologically proven only in the right ovary, but not in the uterus and right fallopian tube. All surgical margins were negative, and one of the 31 lymph nodes retrieved was metastasized by LMS.

Her postoperative course was uneventful. However, 8 months after the surgery, follow-up CT scanning revealed peritoneal and liver metastases. Palliative chemotherapy using gemcitabine (800 mg/m^2^) could not control disease progression, and she died 12 months after the surgery.

3. Discussion {#sec0015}
=============

Since radiological differentiation between LMS and other mesenchymal tumors is difficult, the final diagnosis needs to be confirmed by postoperative pathological examination. The most definitive feature of LMS is immunohistochemical positivity for desmin and SMA, and negativity for DOG 1, CD34, S-100 protein, and c-kit. True LMS resected completely and with tumor free margins is extremely rare, with only 13 reported cases [@bib0030], [@bib0035], [@bib0040], [@bib0045], [@bib0050]. The clinicopathological profiles of these cases and our patient are reviewed in [Table 2](#tbl0010){ref-type="table"}. The tumors ranged 20--106 mm in size, with 5--100 mitoses per 50 HPFs in the previous cases. To the best of our knowledge, LMS in the current study is the largest found the rectum, with the highest mitotic index.

The standard treatment of LMS is complete removal of the tumor [@bib0060]. Since regional lymph node involvement has not been reported in colorectal LMS [@bib0065], the role of extended lymphadenectomy in LMS is controversial [@bib0055]. Some authors have suggested that residual lymph node dissection should be considered in patients with enlarged nodes discovered during the surgical procedure [@bib0070], [@bib0075]. Given that lymph nodes can be metastasized as in our case, lymphadenectomy may be recommended for complete removal of giant LMSs and/or LMSs with prominent mitosis.

The accurate identification and pathologic differentiation between GIST and LMS in the gastrointestinal tract are important because of the excellent response rate of GIST to molecular targeted therapy using tyrosine kinase inhibitors [@bib0080], [@bib0085]. Since the five-year relapse-free survival rate has been reported to be 65%, which is longer than those who did not undergo adjuvant chemotherapy, patients with high-risk GIST are recommended to receive adjuvant imatinib after the complete resection of the tumor [@bib0090]. Additionally, interruption of treatment with imatinib should not be recommended unless patients experience toxic side effects [@bib0095]. Studies have revealed that the use of imatinib for palliative chemotherapy is also effective because the two-year progression free survival (PFS) was 75% with the use of standard imatinib dose in patients with unresectable or metastatic GIST [@bib0100], [@bib0105]. In contrast, it is difficult to assess the efficacy of palliative treatments of LMS due to the paucity of published reports [@bib0110]. Doxorubicin, ifosfamide, dacarbazine, and gemcitabine are commonly used in first-line chemotherapeutic regimens, although standardized chemotherapy with currently available agents has not yet been established for LMS. Additionally, gemcitabine and docetaxel are used as second-line therapy in patients with LMS [@bib0115]; however, response rates of LMS are usually 10%--25% in palliative chemotherapy [@bib0120]. For these reasons, the two-year PFS rate is still reported to be approximately 45%, which is poorer than the prognosis of patients with GIST [@bib0125]. Furthermore, the overall survival of LMS is poor and is reportedly 20%--40% at 5 years [@bib0080], [@bib0130]. Several reports have demonstrated that large tumor size (\>5 cm) and high levels of mitotic activity (\>10/50 HPFs) are unfavorable prognostic factors in LMS [@bib0055], [@bib0060], [@bib0070]. In the present case, a large tumor comprising hyperproliferative cells suggested an unpromising outcome at the time of diagnosis; she experienced early relapse, and only survived an additional 3 months despite chemotherapy with gemcitabine.

4. Conclusion {#sec0020}
=============

In conclusion, we reported a giant LMS of the rectum. It is crucial to diagnose LMS precisely based on immunohistochemistry, and thereby distinguish it from GIST. Although lymph node metastasis is rare, lymphadenectomy appears to be important for high-risk LMSs to perform R0 resection. Further investigation on LMS cases so far is required to establish standard treatment strategies.
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![The colonoscopy showed an elevated tumor with central ulceration in the rectosigmoid.](gr1){#fig0005}

![An axial view of the abdominal CT scan. A giant tumor was found in the space surrounded by the rectosigmoid segment, uterus, and right ovary.](gr2){#fig0010}

![Hematoxylin--eosin staining of the tumor revealed spindle-shaped cells (original magnification: 40×).](gr3){#fig0015}

![Immunohistochemical staining of the tumor. (A) Desmin, (B) IA-4, (C) c-kit, and (D) DOG1 (original magnification: 40×).](gr4){#fig0020}

###### 

Result of Laboratory Tests.

Table 1

  Variable   Unit                 Range
  ---------- ------------ ------- --------------
  WBC        ×1000/μl     10.1    3.5--9.80
  Hb         g/dl         12.7    11.0--15.0
  Hct                     40.4%   38--42%
  Plt        ×10,000/μl   47.8    15.0--45.0
  TP         g/dL         6.1     6.5--8.0
  Alb        g/dL         3.3     3.7--5.2
  ChE        U/L          279     180--420
  AST(GOT)   U/L          20      10--40
  ALT(GPT)   U/L          17      5--40
  γ-GTP      U/L          58      5--24
  T-Bil      mg/dL        0.6     0.2--1.0
  D-Bil      mg/dL        0.1     0.1--0.4
  Ca         mg/dL        8.7     4.5--5.1
  IP         mg/dL        3.0     2.3--4.0
  BUN        mg/dL        12.9    8--20
  Cre        mg/dL        0.59    0.5--0.9
  Na         mEq/L        139     135--146
  K          mEq/L        4.3     3.4--4.8
  Cl         mEq/L        106     98--108
  Amy        U/L          47      50--160
  CK         U/L          116     42--138
  CRP        mg/dL        0.83    \<0.30
  CEA        ng/ml        2.5     \<5.0
  CA19-9     U/ml         19      \<7.0
  PT                      100%    81.0--131.6%
  PT-INR                  0.93    1.0
  APTT       sec          27.6    30--40

###### 

Clinicopathological Profile of reported cases of resected leiomyosarcoma of the rectum.

Table 2

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case   Author         Year of publication   Age/Gender   Tumor\      Macroscopic\     Lymph node metastasis   Immunohistochemistry   Mitoses\   Prognosis                   
                                                           size (mm)   classification                                                  /50HPFs                                
  ------ -------------- --------------------- ------------ ----------- ---------------- ----------------------- ---------------------- ---------- ----------- ---- ---- ----- -------------
  1      Miettinen      2001                  40/Male      35          Polypoid         Absent                  \+                     \+         --          --   --   45    325 M,Alive

  2      Miettinen      2001                  63/Female    20          Polypoid         NS                      \+                     \+         --          --   --   70    191 M,Alive

  3      Miettinen      2001                  52/Male      30          Intramural       NS                      \+                     \+         --          --   --   45    70 M, Dead

  4      Miettinen      2001                  67/Female    30          Plaque-like      NS                      \+                     \+         --          --   --   100   61 M, Dead

  5      Miettinen      2001                  79/Female    25          Polypoid         Absent                  \+                     \+         --          --   --   25    55 M, Dead

  6      Miettinen      2001                  32/Female    23          Polypoid         Absent                  \+                     \+         --          --   --   100   39 M, Alive

  7      Miettinen      2001                  73/Female    NS          NS               NS                      \+                     \+         --          --   --   100   24 M, Dead

  8      Miettinen      2001                  24/Female    55          Polypoid         NS                      \+                     \+         −           --   --   30    NS

  9      Zbar           2004                  65/Female    30          Polypoid         Absent                  \+                     \+         --          NS   --   5     NS

  10     Zbar           2004                  61/Female    70          Polypoid         Absent                  \+                     \+         --          --   --   5     10 M, Dead

  11     Basu           2011                  79/Female    30          Polypoid         NS                      \+                     \+         --          --   --   NS    NS

  12     Yamamoto       2013                  88/Female    65          Ulcerated        Absent                  \+                     \+         --          --   --   38    24 M, Dead

  13     Ouh            2013                  52/Male      106         Stenosis         Absent                  \+                     \+         --          --   NS   100   NS

  14     Present case   --                    76/Female    110         Ulcerated        Present                 \+                     \+         --          --   --   250   12 M, Dead
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SMA = smooth muscle actin; HPF = high power field; NS = not stated; M = months
